| Literature DB >> 27899186 |
Abstract
Familial pancreatic cancer (FPC) includes those kindreds that contain at least two first-degree relatives with pancreatic ductal adenocarcinoma. At least 12 known hereditary syndromes or genes are associated with increased risk of developing pancreatic cancer, the foremost being BRCA2 and CDKN2A. Research into the identification of mutations in known cancer predisposition genes and through next-generation sequencing has revealed extensive heterogeneity. The development of genetic panel testing has enabled genetic risk assessment and predisposition testing to be routinely offered. Precision oncology has opened the possibility of "incidental" germline mutations that may have implications for family members. However, in both cases, evidence-based recommendations for managing patients and at-risk family members in light of genetic status remain emergent, with current practice based on expert opinion. Copyright ÂEntities:
Keywords: BRCA2; CDKN2A; Genetic testing; Pancreatic cancer
Mesh:
Substances:
Year: 2016 PMID: 27899186 PMCID: PMC5234085 DOI: 10.1053/j.seminoncol.2016.09.002
Source DB: PubMed Journal: Semin Oncol ISSN: 0093-7754 Impact factor: 4.929